Would New SARS-CoV-2 Variants Change the War against COVID-19?

被引：3

作者：

Redwan, Elrashdy M. ^{[1
,2
]}

Elrashdy, Fatma ^{[3
]}

Aljabali, Alaa A. A. ^{[4
]}

Baetas-da-Cruz, Wagner ^{[5
]}

Barh, Debmalya ^{[6
,7
]}

Brufsky, Adam M. ^{[8
]}

Hassan, Sk. Sarif ^{[9
]}

Lundstrom, Kenneth ^{[10
]}

Serrano-Aroca, Angel ^{[11
]}

Takayama, Kazuo ^{[12
]}

Tambuwala, Murtaza M. ^{[13
]}

Uhal, Bruce D. ^{[14
]}

Uversky, Vladimir N. ^{[1
,15
,16
]}

机构：

[1] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, POB 80203, Jeddah 21589, Saudi Arabia

[2] City Sci Res & Technol Applicat, Genet Engn & Biotechnol Res Inst, Prot Res Dept, Therapeut & Protect Prot Lab, Alexandria 21934, Egypt

[3] Cairo Univ, Dept Endem Med & Hepatogastroenterol, Cairo 12111, Egypt

[4] Yarmouk Univ, Fac Pharm, Dept Pharmaceut & Pharmaceut Technol, Irbid 566, Jordan

[5] Fed Univ Rio De Janeiro UFRJ, Coll Med, Ctr Expt Surg, Translat Lab Mol Physiol, BR-21941901 Rio De Janeiro, RJ, Brazil

[6] Inst Integrat Om & Appl Biotechnol IIOAB, Purba Medinipur 721172, W Bengal, India

[7] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Genet Ecol & Evolucao, Lab Genet Celular & Mol, BR-31270901 Belo Horizonte, MG, Brazil

[8] Univ Pittsburgh, UPMC Hillman Canc Ctr, Sch Med, Dept Med,Div Hematol Oncol, Pittsburgh, PA 15232 USA

[9] Pingla Thana Mahavidyalaya, Dept Math, Maligram 721140, W Bengal, India

[10] PanTherapeut, Rte Lavaux 49, CH-1095 Lutry, Switzerland

[11] Univ Catolica Valencia San Vicente Martir, Ctr Invest Traslac San Alberto Magno, Biomat & Bioengn Lab, Valencia 46001, Spain

[12] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto 6068507, Japan

[13] Ulster Univ, Sch Pharm & Pharmaceut Sci, Coleraine BT52 1SA, North Ireland

[14] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA

[15] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA

[16] Univ S Florida, USF Hlth Byrd Alzheimers Res Inst, Morsani Coll Med, Tampa, FL 33612 USA

来源：

EPIDEMIOLOGIA | 2022年 / 3卷 / 02期

关键词：

SARS-CoV-2; COVID-19; variant; sublineage; transmission; immunity; infection; vaccination; non-pharmaceutical interventions; HEALTH-CARE WORKERS; VACCINE; CORONAVAC; MULTICENTER; IMMUNITY; ENGLAND; BRAZIL;

D O I：

10.3390/epidemiologia3020018

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The scientific, private, and industrial sectors use a wide variety of technological platforms available to achieve protection against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), including vaccines. However, the virus evolves continually into new highly virulent variants, which might overcome the protection provided by vaccines and may re-expose the population to infections. Mass vaccinations should be continued in combination with more or less mandatory non-pharmaceutical interventions. Therefore, the key questions to be answered are: (i) How to identify the primary and secondary infections of SARS-CoV-2? (ii) Why are neutralizing antibodies not long-lasting in both cases of natural infections and post-vaccinations? (iii) Which are the factors responsible for this decay in neutralizing antibodies? (iv) What strategy could be adapted to develop long-term herd immunity? (v) Is the Spike protein the only vaccine target or is a vaccine cocktail better?

引用

页码：229 / 237

页数：9

共 55 条

[1] Aggarwal NR, 2022, medRxiv, DOI [10.1101/2022.04.03.22273360, 10.1101/2022.04.03.22273360, DOI 10.1101/2022.04.03.22273360]
[2] An update on antiviral antibody-based biopharmaceuticals
Ahangarzadeh, Shahrzad
Payandeh, Zahra
Arezumand, Roghaye
Shahzamani, Kiana
Yarian, Fatemeh
Alibakhshi, Abbas
[J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 86
[3] [Anonymous], 2022, Med Lett Drugs Ther, V64, P64
[4] Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines
Araf, Yusha
Akter, Fariya
Tang, Yan-dong
Fatemi, Rabeya
Parvez, Md Sorwer Alam
Zheng, Chunfu
Hossain, Md Golzar
[J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 1825 - 1832
[5] COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries
Arce, Julio S. Solis
Warren, Shana S.
Meriggi, Niccolo F.
Scacco, Alexandra
McMurry, Nina
Voors, Maarten
Syunyaev, Georgiy
Malik, Amyn Abdul
Aboutajdine, Samya
Adeojo, Opeyemi
Anigo, Deborah
Armand, Alex
Asad, Saher
Atyera, Martin
Augsburg, Britta
Awasthi, Manisha
Ayesiga, Gloria Eden
Bancalari, Antonella
Nyqvist, Martina Bjorkman
Borisova, Ekaterina
Bosancianu, Constantin Manuel
Cabra Garcia, Magarita Rosa
Cheema, Ali
Collins, Elliott
Cuccaro, Filippo
Farooqi, Ahsan Zia
Fatima, Tatheer
Fracchia, Mattia
Galindo Soria, Mery Len
Guariso, Andrea
Hasanain, Ali
Jaramillo, Sofia
Kallon, Sellu
Kamwesigye, Anthony
Kharel, Arjun
Kreps, Sarah
Levine, Madison
Littman, Rebecca
Malik, Mohammad
Manirabaruta, Gisele
Mfura, Jean Leodomir Habarimana
Momoh, Fatoma
Mucauque, Alberto
Mussa, Imamo
Nsabimana, Jean Aime
Obara, Isaac
Juliana Otalora, Maria
Ouedraogo, Bechir Wendemi
Pare, Touba Bakary
Platas, Melina R.
[J]. NATURE MEDICINE, 2021, 27 (08) : 1385 - +
[6] Five reasons why COVID herd immunity is probably impossible
Aschwanden, Christie
[J]. NATURE, 2021, 591 (7851) : 520 - 522
[7] Bard JD., 2021, medRxiv, DOI [10.1101/2021.05.22.21257660, DOI 10.1101/2021.05.22.21257660]
[8] Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
Bosnjak, Berislav
Stein, Saskia Catherina
Willenzon, Stefanie
Cordes, Anne Katrin
Puppe, Wolfram
Bernhardt, Guenter
Ravens, Inga
Ritter, Christiane
Schultze-Florey, Christian R.
Goedecke, Nina
Martens, Joerg
Kleine-Weber, Hannah
Hoffmann, Markus
Cossmann, Anne
Yilmaz, Mustafa
Pink, Isabelle
Hoeper, Marius M.
Behrens, Georg M. N.
Poehlmann, Stefan
Blasczyk, Rainer
Schulz, Thomas F.
Foerster, Reinhold
[J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (04) : 936 - 944
[9] Risk of SARS-CoV-2 reinfection after natural infection
Boyton, Rosemary J.
Altmann, Daniel M.
[J]. LANCET, 2021, 397 (10280) : 1161 - 1163
[10] Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2

← 1 2 3 4 5 6 →